Rankings / Longevity — Supplements
Plasma exchange / young plasma
Longevity · Dilutional therapeutic
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades Plasma exchange / young plasma as D (3.3/10) based on weak evidence, low-med benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Conboy lab 2020 showed neutral saline + albumin exchange had rejuvenating effects similar to young plasma — pointing to a dilution mechanism, not 'youth factors.
Studied, labeled, or reported-use context: Clinical TPE protocols — weekly for several sessions — Research/clinical setting; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
Heterochronic parabiosis produced real rejuvenation effects in mice across multiple tissues, and the follow-up work suggests dilution of age-elevated factors matters more than any youthful factor — which is a mechanism plasma exchange can actually act on. One small human RCT reported biological-age reductions.
Why it may not get there
Parabiosis shares an entire circulatory system continuously; a few hours of apheresis is a weak analogue. The human evidence is one small trial using epigenetic-clock endpoints that are themselves unvalidated as outcome surrogates. The procedure is invasive, expensive, requires clinical supervision, and carries citrate-reaction and line risks.
What would change this A randomised trial with a functional endpoint rather than a biological-age clock.
What the evidence says
Conboy lab 2020 showed neutral saline + albumin exchange had rejuvenating effects similar to young plasma — pointing to a dilution mechanism, not 'youth factors.' FDA 2019 warned against Ambrosia-style young-plasma transfusions for anti-aging. New human data: a single-blinded, placebo-controlled RCT (Fuentealba/Kiprov, Aging Cell 2025, n=42) found repeated therapeutic plasma exchange (TPE) lowered biological-age clocks — roughly 1.3 years with TPE alone and 2.6 years with TPE+IVIG — with an acceptable safety profile (2 AEs requiring discontinuation). A May 2026 preprint (Lauc/GlycanAge, n=20,405 across 42 studies) validated the IgG N-glycome as a modifiable biological-age biomarker and ranked TPE the largest per-month reducer (HRT and caloric restriction also lowered it) — preprint, not yet peer-reviewed. Evidence remains small-N on surrogate clocks, not hard outcomes; TPE is invasive, costly, and clinic-only.
Mechanism
Therapeutic plasma exchange (TPE) removes pro-aging factors (dilution of 'bad' blood) OR replaces with young plasma; Conboy lab shows dilution alone may be sufficient
Studied, labeled, or reported dose & route
Clinical TPE protocols — weekly for several sessions
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Plasma exchange / young plasma's effects?
- Read Off Label rates the evidence for Plasma exchange / young plasma as Weak and the benefit magnitude as low-med, producing an overall grade of D (3.3/10). Conboy lab 2020 showed neutral saline + albumin exchange had rejuvenating effects similar to young plasma — pointing to a dilution mechanism, not 'youth factors.
- What safety findings are reported for Plasma exchange / young plasma?
- Plasma exchange / young plasma has a med-high risk profile in the database. Med-High (infection, immune, cost) Legal status: Research/clinical setting.
- What does the low Safety score for Plasma exchange / young plasma represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Plasma exchange / young plasma?
- Clinical TPE protocols — weekly for several sessions This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Plasma exchange / young plasma work?
- Therapeutic plasma exchange (TPE) removes pro-aging factors (dilution of 'bad' blood) OR replaces with young plasma; Conboy lab shows dilution alone may be sufficient
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.